Clinical pharmacology of benoxaprofen

Eating does not modify benoxaprofen blood concentrations. Combining benoxaprofen with tolbutamide does not significantly change plasma glucose, insulin, or tolbutamide concentrations. Probenecid, by blocking renal tubular secretion of benoxaprofen, increases the benoxaprofen half-life and decreases...

Full description

Saved in:
Bibliographic Details
Published inEuropean journal of rheumatology and inflammation Vol. 5; no. 2; p. 98
Main Authors Ridolfo, A S, Carmichael, R H, DeSante, K A, Bergstrom, R F, Rockhold, F W, Nash, J F, Fineberg, S E
Format Journal Article
LanguageEnglish
Published England 1982
Subjects
Adult
Aged
Anti-Inflammatory Agents - blood
Anti-Inflammatory Agents - metabolism
Anti-Inflammatory Agents - urine
Binding, Competitive
Creatinine - metabolism
Food
Humans
Hypoglycemic Agents - blood
Kidney - drug effects
Kidney - metabolism
Kidney Tubules - metabolism
Middle Aged
Probenecid - pharmacology
Propionates - blood
Propionates - metabolism
Propionates - urine
Online AccessGet more information

Cover

More Information
Summary:Eating does not modify benoxaprofen blood concentrations. Combining benoxaprofen with tolbutamide does not significantly change plasma glucose, insulin, or tolbutamide concentrations. Probenecid, by blocking renal tubular secretion of benoxaprofen, increases the benoxaprofen half-life and decreases its renal clearance and urinary excretion. Excretion rate is halved in patients with severe renal impairment. Hemodialysis inefficiently lowers benoxaprofen plasma concentrations. Neither glomerular nor renal tubular function is affected by benoxaprofen, even after five years of therapy. The incidence in urine of microscopic spheroids (benoxaprofen glucuronide complexes) is related to urinary drug concentration and osmolality; increasing the fluid intake decreases incidence.
ISSN:0140-1610